SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Introgen Therapeutics
An SI Board Since February 2004
Posts SubjectMarks Bans Symbol
802 21 0 INGN
Emcee:  tuck Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromPosted
327Agreed..not much new except that Jack Roth is a big league researcher in this fizeta19616/2/2005
326In the mean time they continue to treat head & neck cancer patients with p53Jibacoa6/2/2005
325ASGT news, most of it incremental or old, not much effect on stock price . . tuck6/2/2005
324Bernard..thanks..I needed that today! Immediate delivery (using cyber vector-g-zeta19616/1/2005
323<i> According to this author, INGN's chances for AA are 'nil, zip.Jibacoa6/1/2005
322Message 21374268 According to this author, INGN's chances for AA are 'nzeta19615/31/2005
321Phase II Study of Combination Cisplatin, Docetaxel and <b>Erlotinib</b&zeta19615/31/2005
320Who needs Advexin when you've got N-Acetyl-Cysteine over the counter?-g- fozeta19615/30/2005
319ooppppssssssss wrong board..no message..Zetazeta19615/30/2005
318<i>be sure to let us know if you have any new insight on the subject afterzeta19615/30/2005
317It seems you have been busy and are doing some research on P53.<g> Here iJibacoa5/29/2005
316Comparison of p53 genotype and phenotype: Site of mutation predicts outcome in pzeta19615/28/2005
315Cell cycle control and apoptosis of p53-isogenic cell lines treated with Hsp90 izeta19615/28/2005
314Diffuse and/or superficial p53 expression in Barrett mucosa correlates with sevezeta19615/28/2005
313p53 mutation as a determinant of prognosis in GIST patients treated with Imatinizeta19615/28/2005
312From YMB bud re: prior abstract's PCI technology.. This article reviews a nzeta19615/28/2005
311Eradication of p53-mutated head and neck squamous cell carcinoma (HNSCC) xenograzeta19615/28/2005
310Prognostic value of abnormal p53 expression in locally advanced prostate cancer zeta19615/28/2005
309Correlation of p53 genotype and response to induction chemotherapy in advanced nzeta19615/28/2005
308Thanks Tuck..wonder how much mileage a Liter of adenovirus gets ya' Zetazeta19615/25/2005
307Here's a link to their capacity for adenovirus prodcution (I presume thattuck5/25/2005
306iii.co.uk Apparently INGN entered a manufacturing agreement with this co.zeta19615/25/2005
305Parking SCLC ASCO '03 slides..comprehensive look @ treatment history and prozeta19615/21/2005
304INNG Made Some Comments on INGN 401.<g> Bernard <b>Introgen's Jibacoa5/17/2005
303Journal of Clinical Oncology, Vol 17, Issue 6 (June), 1999: 1794 [full text of zeta19615/17/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News